Elsner Viviane Rostirola, Trevizol Lucieli, de Leon Isadora, da Silva Marcos, Weiss Thayná, Braga Milena, Pochmann Daniela, Blembeel Amanda Stolzenberg, Dani Caroline, Boggio Elenice
Curso de Fisioterapia do Centro Universitário Metodista-IPA; Programa de Pós-Graduação em Biociências e Reabilitação do Centro Universitário Metodista-IPA; Programa de Pós-Graduação em Ciências Biológicas: Fisiologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil.
Curso de Fisioterapia do Centro Universitário Metodista-IPA, Porto Alegre, RS, Brasil.
Neural Regen Res. 2021 May;16(5):805-812. doi: 10.4103/1673-5374.297078.
A growing body of evidence has suggested that the imbalance of epigenetic markers and oxidative stress appears to be involved in the pathophysiology and progression of stroke. Thus, strategies that modulate these biomarkers might be considered targets for neuroprotection and novel therapeutic opportunities for these patients. Physical exercise has been reported to induce changes in these epigenetic markers and improve clinical outcomes in different populations. However, little is reported on this in post-stroke patients. The purpose of this study was to investigate the effect of a single exercise session with WalkAide functional electrical stimulation (FES) on cognitive performance, clinical functional parameters, oxidative stress and epigenetic modulation in post-stroke individuals. In this crossover design study, 12 post-stroke individuals aged 54-72 years of either sexes were included and subjected to a single session of exercise (45 minutes) without WalkAide functional electrical stimulation (EXE alone group), followed by another single session of exercise (45 minutes) with WalkAide functional electrical stimulation (EXE + FES group). The clinical functional outcome measures, cognitive performance and blood collections for biomarker measurements were assessed pre- and post-intervention. After intervention, higher Berg Balance Scale scores were obtained in the EXE + FES group than in the EXE alone group. There was no significant difference in the Timed Up and Go test results post-intervention between EXE alone and EXE + FES groups. After intervention, a better cognitive performance was found in both groups compared with before the intervention. After intervention, the Timed Up and Go test scores were higher in the EXE + FES group than in the EXE alone group. In addition, the intervention induced lower levels of lipid peroxidation. After intervention, carbonyl level was lower, superoxide dismutase activity and superoxide dismutase/catalase activity ratio were higher in the EXE + FES group, compared with the EXE group alone. In each group, both histone deacetylase (HDAC2) and histone acetyltransferase activities were increased after intervention compared with before the intervention. These findings suggest that a single exercise session with WalkAide FES is more effective on balance ability and cognitive performance compared with conventional exercise alone in post-stroke patients. This is likely to be related to the regulation of oxidative stress markers. The present study was approved by the Research Ethics Committee of the Methodist University Center-IPA (approval No. 2.423.376) on December 7, 2017 and registered in the Brazilian Registry of Clinical Trials-ReBEC (RBR-9phj2q) on February 11, 2019.
越来越多的证据表明,表观遗传标记物的失衡和氧化应激似乎与中风的病理生理学和进展有关。因此,调节这些生物标志物的策略可能被视为神经保护的靶点以及为这些患者提供新的治疗机会。据报道,体育锻炼会引起这些表观遗传标记物的变化,并改善不同人群的临床结局。然而,关于中风后患者的这方面报道很少。本研究的目的是调查单次使用WalkAide功能性电刺激(FES)进行锻炼对中风后个体的认知表现、临床功能参数、氧化应激和表观遗传调节的影响。在这项交叉设计研究中,纳入了12名年龄在54 - 72岁之间的中风后个体,他们被分为两组,一组进行单次45分钟的无WalkAide功能性电刺激的锻炼(仅锻炼组),随后进行另一单次45分钟的有WalkAide功能性电刺激的锻炼(锻炼 + FES组)。在干预前后评估临床功能结局指标、认知表现以及用于生物标志物测量的血液采集情况。干预后,锻炼 + FES组的伯格平衡量表得分高于仅锻炼组。仅锻炼组和锻炼 + FES组干预后的定时起立行走测试结果没有显著差异。干预后,两组的认知表现均比干预前有所改善。干预后,锻炼 + FES组的定时起立行走测试得分高于仅锻炼组。此外,干预使脂质过氧化水平降低。干预后,与仅锻炼组相比,锻炼 + FES组的羰基水平更低,超氧化物歧化酶活性和超氧化物歧化酶/过氧化氢酶活性比值更高。在每组中,与干预前相比,干预后组蛋白去乙酰化酶(HDAC2)和组蛋白乙酰转移酶活性均增加。这些发现表明,与中风后患者单纯进行传统锻炼相比,单次使用WalkAide FES进行锻炼对平衡能力和认知表现更有效。这可能与氧化应激标志物的调节有关。本研究于2017年12月7日获得卫理公会大学中心 - IPA研究伦理委员会批准(批准号2.423.376),并于2019年2月11日在巴西临床试验注册中心 - ReBEC注册(注册号RBR - 9phj2q)。